Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Milla Follows Sandoz Partnership With Shortage-Hit Sodium Acetate Launch

Sandoz Launched Milla-Developed Acetaminophen Injectable Last Year

Executive Summary

Milla Pharmaceuticals, part of the Alter Pharma Group, toasted three milestones as it announced approval and launch of its generic version of Pfizer’s sodium acetate 2mEq/ml injectable in the US.

You may also be interested in...



Hyloris Buys Out Maxigesic IV Royalty Rights From Alter Pharma

Belgian value-added medicines specialist Hyloris Pharmaceuticals has renegotiated its licensing agreement with Alter Pharma group, wrapping up all previous agreements. Under the new agreement, Hyloris will forego all past commitments and all further future royalty obligations to Alter for Maxigesic IV.

FDA’s OGD Takes Fight To COVID-19 With Half-Century Of Approvals

The sixth annual report of the FDA’s Office of Generic Drugs covered a year dominated by the novel coronavirus pandemic – although first-time generic approvals and record levels of communication also featured prominently.

Slayback Exclusivity On Taytulla Does Not Bar Rival ANDA Product

Slayback Pharma has now launched its Merzee generic version of Allergan’s Taytulla oral contraceptive with a CGT designation, several months after Xiromed moved first.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB151198

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel